MRK is up over 32% in three months, but declining estimates, Keytruda's upcoming LOE and Gardasil declines keep the stock ...

Shame can shape how early patients get diagnosed, and how aggressively they pursue treatment, if at all. In a 2014 study, Dr.

Both biotechs are a bit risky, but could benefit from clinical progress this year -- and the upside would be huge. CRISPR has ...

Select your location to view local American Lung Association events and news near you.

A meaningful portion of Merck’s MRK revenues comes from its oncology franchise anchored by its blockbuster PD-L1 inhibitor, ...

The early-stage clinical trial marks the first U.S. testing of Alveltamig, an immunotherapy designed to help the immune ...

Coherus Oncology, Inc. ( CHRS) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 1:30 PM EST Good morning everyone. It's still the morning. Thanks for joining us for another session at ...

A key number for Merck in the coming years is $70 billion. This is the mid-2030s revenue opportunity from potential new ...

New data show cancer survival has reached a record high — nearly 70% of patients now live at least five years after diagnosis ...

At the JP Morgan Healthcare Conference, the firm highlighted two antibody-drug conjugates among 10 programs that will fuel ...

Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all ...

Lung cancer kills more Americans each year than any other cancer — yet most Americans are uninformed about this disease. A ...